GSK to review CCI order
NEW DELHI: GlaxoSmithKline Pharmaceuticals (GSK) will review the order passed by Competition Commission of India (CCI) and consider all options, including filing an appeal, the company said. The CCI levied penalty to the extent of 3 percent of the turnover both on GSK and Sanofi, aggregating to 60.49 crore and 3.04 crore, respectively
Tags:GlaxoSmithKline to review CCI order, GSK,CCI, Sanofi,
